Breast Cancer Clinical Trial
Official title:
Phase I Study of the HSP-90 Inhibitor, AT13387, in Adults With Refractory Solid Tumors
Background:
- The experimental drug AT13387 has been shown to have some anticancer effects against tumor
cells by blocking a protein that affects other proteins inside certain cancer cells, and
helps to prevent the cancer cells from reproducing and spreading. AT13387 has not been tested
in humans, and researchers are interested in investigating whether it can be used to treat
solid tumors that have not responded to standard treatments.
Objectives:
- To investigate the safety and effectiveness of AT13387 in individuals with solid tumors.
Eligibility:
- Individuals at least 18 years of age who have solid tumors that have not responded to
standard treatments.
Design:
- Participants will be screened with a physical examination and medical history, as well
as blood tests and tumor imaging studies.
- AT13387 will be given in 28-day cycles of treatment. Participants will receive AT13387
twice a week (2 days in a row) for the first 3 weeks of the cycle, followed by a fourth
week without the drug.
- Participants will have regular blood and urine samples, imaging studies, eye
examinations, and tumor biopsies to monitor the effects of the treatment.
- Participants will continue treatment with AT13387 unless serious side effects develop or
the tumor stops responding to treatment.
Background:
- AT13387 is a synthetic Hsp90 inhibitor that has demonstrated improved characteristics
over other Hsp90 inhibitors. AT13387 has a long tumor retention half-life and prolonged
inhibitory effect on its known oncogenic client proteins.
- AT13387 has demonstrated activity against multiple cancer cell lines and tumor
xenografts in pre-clinical models.
Primary Objectives:
- Define the safety and tolerability of AT13387 administered on a QDx2 every week, 3 weeks
out of 4 scheduled, in adults with refractory solid tumors.
- Establish the maximum tolerated dose (MTD) of AT13387 administered on a QDx2 every week,
3 weeks out of 4 schedule, in adults with refractory solid tumors.
Secondary Objectives:
- Determine the pharmacokinetics (PK) of AT13387 administered on a QDx2 every week, 3
weeks out of 4 schedule, in adults with refractory solid tumors.
- Assess pharmacodynamic (PD) markers of Hsp90 inhibition and modulation of Hsp90 client
proteins by AT13387 in tumor tissue, serum, and PBMCs.
Eligibility:
-Study participants must have histologically confirmed solid tumor malignancy that has
progressed or recurred after at least one line of chemotherapy, or for which no standard
treatment option exists. Participants enrolling in the expansion phase must have disease
amenable to biopsy with willingness to undergo pre- and post-treatment biopsies (Remove the
HER 2 archival tissue).
Study Design:
- This study will follow an accelerated titration design 2B with initial dose levels
increased in 100% increments.
- The accelerated phase ends when one patient experiences a dose-limiting toxicity or two
patients experience Grade 2 drug-related toxicity during the first cycle; when dose
level 3 is reached; or at first instance of Grade 2 ocular toxicity in any cycle.
- AT13387 will be administered intravenously, over 1 hour, on 2 consecutive days, 3 out of
4 weeks, every 28 days (i.e., on days 1, 2, 8, 9, 15, and 16 of each 28-day cycle).
- PK and PD studies will be conducted in cycle 1 only. Once the MTD is established, 10
additional patients, will be entered at the MTD to further define toxicity and perform
PD studies at this dose; pre- and post-treatment tumor biopsies will be mandatory for
these patients.
- CT scans will be performed at baseline and every 2 cycles for restaging.
- Up to 37 patients may be treated.
- Study participants will be offered optional participation in an ongoing NCI imaging
study at baseline with a repeat scan following the last dose of AT13387 in cycle 1.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A |